Page last updated: 2024-08-26

mafosfamide and cyc 202

mafosfamide has been researched along with cyc 202 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Błoński, JZ; Kiliańska, ZM; Robak, T; Wesierska-Gadek, J; Zolnierczyk, JD	1
Borowiak, A; Błoński, JZ; Cebula-Obrzut, B; Kiliańska, ZM; Komina, O; Robak, P; Smolewski, P; Węsierska-Gądek, J; Żołnierczyk, JD	1

Other Studies

2 other study(ies) available for mafosfamide and cyc 202

Article	Year
Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide. Annals of the New York Academy of Sciences, 2009, Volume: 1171 Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Caspase 9; Cell Survival; Cells, Cultured; Cladribine; Cyclin E; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclophosphamide; Drug Synergism; Female; Flow Cytometry; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Purines; Roscovitine; Vidarabine	2009
Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line; Cladribine; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Purines; Roscovitine; Vidarabine	2012

Article

Year

Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide.

Annals of the New York Academy of Sciences, 2009, Volume: 1171

Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Caspase 9; Cell Survival; Cells, Cultured; Cladribine; Cyclin E; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclophosphamide; Drug Synergism; Female; Flow Cytometry; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Purines; Roscovitine; Vidarabine

2009

Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment.

Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:3

Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line; Cladribine; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Purines; Roscovitine; Vidarabine

2012